Sanofi
SNY
488 hedge funds and large institutions have $8.02B invested in Sanofi in 2019 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 142 increasing their positions, 197 reducing their positions, and 54 closing their positions.
273% more call options, than puts
Call options by funds: $61.3M | Put options by funds: $16.4M
3% more capital invested
Capital invested by funds: $7.77B → $8.02B (+$254M)
0.23% more ownership
Funds ownership: 14.29% → 14.52% (+0.23%)
4% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 54
2% less funds holding
Funds holding: 500 → 488 (-12)
28% less repeat investments, than reductions
Existing positions increased: 142 | Existing positions reduced: 197
36% less funds holding in top 10
Funds holding in top 10: 14 → 9 (-5)
Top Buyers
| 1 |
Lazard Asset Management
New York
|
+$102M |
| 2 |
Charles Schwab
San Francisco,
California
|
+$43.5M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$29.9M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$20.1M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
+$19.7M |
Top Sellers
SNY Hedge Fund Activity: Q1 2019 in Review
488 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q1 2019, worth a combined $8.02B — up 3.3% from $7.77B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of SNY and 52 opened new positions — a net loss of 2 holders — while 197 trimmed existing stakes and 142 added.
The largest buyer was Lazard Asset Management, adding an estimated $102M. The largest seller was Hotchkis & Wiley Capital Management, cutting an estimated $70M.
- 488 institutional investors held Sanofi (SNY) as of Q1 2019, down from 500 in Q4 2018.
- Funds reported $8.02B of Sanofi stock for Q1 2019, up 3.3% quarter-over-quarter.
- 52 funds opened new Sanofi positions in Q1 2019 and 54 closed out, a net change of -2 holders.
- The largest Sanofi buyer in Q1 2019 was Lazard Asset Management, an estimated $102M added.
- The largest Sanofi seller in Q1 2019 was Hotchkis & Wiley Capital Management, an estimated $70M sold.
Based on aggregated 13F filings for Q1 2019.